Eugene Oh

This study shows that truncating mutations in PPM1D shift its degradation pathway from ubiquitin-independent to UBR5-mediated, leading to increased PPM1D levels and oncogenic effects.

The paper identifies HECTD4 as a tumor and metastasis suppressor that targets COX-2 for degradation, with COX-2 stabilization driving pro-tumorigenic effects in breast cancer.

The paper shows genomic uracil induces DNA replication stress without BER processing and identifies UNG2 upregulation as a vulnerability in cancer cells.

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.